All Posts
Winter 2023-2024 Community Fundraiser Highlights
This winter, our Community Fundraisers created new ways to raise funds for much-needed research and programs and to shine a…
Herizon BTC-302 An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard of care therapy alone for advanced HER2 positive biliary tract cancer
Study Name Herizon BTC-302 An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against…
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
Study Name A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects…
Scientific Update: Webinar Recap - Immunotherapy Insights for Cholangiocarcinoma
In a CCF webinar, Dr. Haley Ellis provided an overview of recent advances in immunotherapy for cholangiocarcinoma. These cutting-edge therapies…
Cholangiocarcinoma Awareness Month Highlights 2024
Awareness Month 2024 was the most inspiring yet! Thank you to all who participated in Cholangiocarcinoma Awareness Month this past…
Scientific Update: FGFR2 Pathway Activation as a Therapeutic Biomarker for FGFR2 Inhibitors
Fibroblast growth factor receptor 2 (FGFR2) is among cholangiocarcinoma's most frequently altered genes. Chromosomal fusions and gene rearrangements are particularly…
From Football to Fine Art - A family finds creative ways to raise funds and awareness
In the summer of 2022, Taylor's family received devastating news: her dad had been diagnosed with cholangiocarcinoma. As a first…
Strength in Community, Hope in Research: Creating a World Free of Cholangiocarcinoma
In October of 2005, my brother, Mark, was diagnosed with cholangiocarcinoma, a rare and aggressive cancer of the bile duct,…
Scientific Update: Phase II Study of a Novel Immunotherapy Combination for Cholangiocarcinoma
Kelly Butler The first line of treatment for unresectable cholangiocarcinoma is gemcitabine plus cisplatin, a combination of two traditional chemotherapies…
NCI/CTEP 10276: A Phase 1/2 Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
Study Name NCI/CTEP 10276: A Phase 1/2 Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with…